Abstract
Tumor necrosis factor (TNF), interleukin-1 (IL-1) and IL-6 are considered master cytokines in chronic destructive arthritis. IL-1 drives chronic erosive arthritis and its blockade has been shown to ameliorate joint destruction in many animal models of arthritis. This ranges from a dominant role of IL-1 in immune complex arthritis, to a key role in development of T cell-dependent arthritis and TNF transgenic arthritis. This makes IL-1 an attractive therapeutic target, in addition to TNF and IL-6. However, IL-1 dependency can be lost under conditions of T cell IL-17 abundance as well as the presence of Toll-like receptor ligands. The latter may underlie the variable responsiveness of rheumatoid arthritis patients to anti-cytokine therapy and warrants combination therapy for optimal control.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
van Lent PL, Grevers L, Lubberts E, de Vries TJ, Nabbe KC, Verbeek S, Oppers B, Sloetjes A, Blom AB, van den Berg WB (2006) FcgammaRs directly mediate cartilage but not bone destruction in murine antigen induced arthritis: Uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum 54: 3868–77
Schaefer L, Babelova A, Kiss E, Hausse HJ, Baliova M, Kryzankova M, Marsche G, Young MF, Mihalik D, Gotte M et al (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223–2233
Arend WP, Dayer JM (1995) Inhibition of the production and effects of IL-1 and TNFα in RA. Arthritis Rheum 38: 151–160
Sims JE, Nicklin MJ, Bazan JF, Barton JL, Busfield SJ, Ford JE, Kastelein RA, Kumar S, Lin H, Mulero JJ et al (2001) A new nomenclature for IL-1-family genes. Trends Immunol 22: 536–537
Burger D, Dayer JM, Palmer G, Gabay C (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20: 879–96
Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355–1359
Tschopp J, Martinon F, Burns K et al (2003) NALPs: A novel protein family involved in inflammation. Nat Rev Mol Cell Biol 4: 95–104
Elssner A, Duncan M, Gavrilin M, Wevers MD (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172: 4987–4994
Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, Leimer AH, Chernis J (1999) Converting enzyme-independent release of TNFα and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci USA 96: 6261–6266
Janssens S, Beyaert R (2003) Functional diversity and regulation of different interleukin-1 receptor associated kinases (IRAK) family members. Mol Cell 11: 293–302
Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FA (2005) Soluble IL-1RacP ameliorates collagen induced arthritis by a different mode of action from that of IL-1ra. Arthritis Rheum 52: 2202–11
Bresnihan B, Newmark R, Robbins S, Genant HK (2004) Effects of Anakinra monotherapy on joint damage in patients with RA. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 31: 1103–11
Van de Loo A.A.J. van den Berg WB (1990) Effects of murine recombinant IL-1 on synovial joint in mice: Measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 49: 238–245
Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, Fujikawa K, Tada N (2001) Macrophage and neutrophil dominant arthritis in human IL-1 alpha transgenic mice J Clin Invest 107: 1127–35
Niki Y, Yamada H, Kikuchi T, Toyama Y, Matsumoto H, Fujikawa K, Tada N (2004) Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1alpha transgenic mice. J Immunol 172: 577–84
Probert L, Plows D, Kontogerogos G, Kollias G (1995) The type I IL-1 receptor acts in series with TNFα to induce arthritis in TNFα transgenic mice. Eur J Immunol 25: 1794–97
Zwerina J, Redlich K, Polzer K, Joosten LA, Kroenke G, Distler J, Hess A, Pundt N, Pap T, Hoffman O et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104: 11742–47
Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115: 282–290
Joosten LA, Helsen MA, van de Loo FA, van den Berg WB (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39: 797–809
Mori L, Iselin S, Delibero G, Lesslauer W (1996) Attenuation of collagen-induced arthritis in 55-kD TNF receptor type I (TNFR1)-IgG1 treated and TNFR1-deficient mice. J Immunol 157: 3178–3182
Campbell IK, O’Donnel K, Lawlor KE, Wicks IP (2001) Severe inflammatory arthritis and lymphadenopathy on the absence of TNF. J Clin Invest 107: 1519–1527
Alten RH, Pohl CC, Batard YY, Wright AA, Gram HH, Bobadilla MM (2006) ACR 20/50/70 responses in MTX resistant RA patients in a double blind, placebo controlled phase 1/II evaluation of the pharmacokinetics / pharmacodynamics, safety, and preliminary efficacy of a fully human anti-IL-1β monoclonal antibody ACZ8985. Ann Rheum Dis 65 (Suppl II): 60
Ma YS, Thornton GP, Boivin D, Hirsch R, Hirsch E (1998) Altered susceptibility to collagen induced arthritis in transgenic mice with aberrant expression of IL-1ra. Arthritis Rheum 41: 1798–1805
Lubberts E, Koenders MI, van den Berg WB (2005) The role of IL-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther 7: 29–37
van de Loo FAJ, Joosten LAB, van Lent PL, Arntz OJ, van den Berg WB (1995) Role of IL-1, TNF and IL-6 in cartilage proteoglycan metabolism and destruction: Effect of in situ cytokine blocking in murine antigen and zymosan induced arthritis. Arthritis Rheum 38: 164–72
van Meurs JBJ, van Lent PL, Singer II, Bayne EK, van de Loo FAJ, van den Berg WB (1998) IL-1ra prevents expression of the metalloproteinase generated neoepitope VDIPEN in antigen induced arthritis. Arthritis Rheum 41: 647–56
Koenders MI, Lubberst E, Oppers-Walgreen B, van den Bersselaar L, Helsen MMA, DiPadova FE, Boots AM, Gram H, Joosten LA, van den Berg WB (2005) Blocking of IL-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1. Am J Pathol 167: 141–49
van Lent PL, van de Loo FA, Holthuysen AE, van den Bersselaar LA, Vermeer H, van den Berg WB (1995) Major role for IL-1 but not for TNF in early cartilage damage in immune complex arthritis in mice. J Rheumatol 22: 2250–58
Monach PI, Benoist C, Mathis D (2004) The role of antibodies in mouse models of RA and relevance to human disease. Adv Immunol 82: 217–48
Nigrovic PA, Binstadt BA, Monach PA, Johnson A, Gurish M, Iwakura Y, Benoist C, Mathis D, Lee DM (2007) Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci USA 104: 2325–30
Bendele AM, Chipala ES, Scherrer J, Frazier J, Sennelo G, Rich WJ, Edwards CK III (2000) Combination benefit of treatment with the cytokine inhibitors IL-1ra and PEGylated soluble TNF receptor type I in animals of rheumatoid arthritis. Arthritis Rheum 43: 2648–59
Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y (2000) Development of chronic inflammatory arthropathy resembling RA in IL-1ra deficient mice. J Exp Med 191: 313–20
Horai R, Nakajima A, Habiro K, Kotani M, Nakae S, Matsuki T, Nambu A, Saijo S, Kotaki H, Sudo K et al (2004) TNFα is crucial for the development of autoimmune arthritis in IL-1ra deficient mice. J Clin Invest 114: 1603–11
Nakae S, Saiijo S, Horai R, Sudo K, Mori S, Iwakura Y (2003) Il-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1ra. Proc Natl Acad Sci USA 100: 5986–90
Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T et al (2004) Distinct contribution of IL-6, TNFα, IL-1 and IL-10 to T cell mediated spontaneous autoimmune arthritis in mice. J Clin Invest 114: 582–8
Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S (2007) T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17 Th cells that cause autoimmune arthritis. J Exp Med 204: 41–7
Sawa S, Kamimura D, Jin GH, Morikawa H, Kamon H, Nishihara M, Ishihara K, Murakami M, Hirano T (2006) Autoimmune arthritis associated with mutated IL-6 receptor gp130 is driven by STAT3/IL-7 dependent homeostatic proliferation of CD4+ T cells. J Exp Med 203: 1459–70
van den Berg WB, Joosten LA, van de Loo FA (1999) TNFα and IL-1β are separate targets in chronic arthritis. Clin Exp Rheumatol 17 (Suppl 18) S105–114
van den Berg WB (2001) Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res Ther 3: 18–26
Joosten LA, Abdollahi-Roodsaz S, Heuvelmans M, Helsen MM, van den Bersselaar LA, Oppers-Walgreen B, Koenders MI, van den Berg WB (2008) T cell dependency of chronic destructive arthritis induced by repeated local activation of TLR-driven pathways: Crucial role for both IL-1beta and IL-17. Arthritis Rheum 58: 98–108
Lubberts E, Schwarzenberger P, Huang W, Schurr JR, Peschon JJ, van den Berg WB, Kolls JK (2005) Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 175: 3360–68
O’Sullivan BJ, Thomas HE, Pai S, Santamaria P, Iwakura Y, Steptoe RJ, Kay TW, Thomas R (2006) IL-1β breaks tolerance through expansion of CD25+ effector cells. J Immunol 176: 7278–87
Koenders MI, Lubberts E, van de Loo FA, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Joosten LA, van den Berg WB (2006) IL-17 acts independently of TNFβ under arthritic conditions. J Immunol 176: 6262–69
Choe JY, Crain B, Wu SR, Corr M (2003) IL-1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor-4 signaling. J Exp Med 197: 537–42
Kalliolas GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: Experience from an uncontrolled trial. Ann Rheum Dis 66: 842–3
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
van den Berg, W.B., Joosten, L.A.B., van de Loo, F.A.J. (2009). Role of IL-1 in erosive arthritis, lessons from animal models. In: Tak, PP. (eds) New Therapeutic Targets in Rheumatoid Arthritis. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8238-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8238-4_4
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8237-7
Online ISBN: 978-3-7643-8238-4
eBook Packages: MedicineMedicine (R0)